Biomarkers for the Diagnosis of Transient Ischemic Attack

Cerebrovascular Disorders Clinical Trial

— MAESTRO  

Official title:

Biomarkers for the Diagnosis of Transient Ischemic Attack

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02799511
• Other study ID #: 2014-A00346-41
• Status: Completed
• Phase: N/A
• Start date: March 2015
• Est. completion date: September 2019

Study information

• Verified date: December 2019
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A transient ischemic attack (TIA) should be considered an emergency prevention opportunity in order to avoid recurrence as cerebral infarction (CI) serious (fatal or disabling). Indeed, about 20% of patients who have IC had in previous days or weeks, a TIA, which can be defined as a brief episode of cerebral dysfunction (or eye) do not result in permanent brain damage and thus no sequelae. Moreover, about 20% of ischemic events observed in practice are AIT. Despite the progress achieved in the treatment in the acute phase of an IC, prevention remains the most effective way to fight against this disease. This prevention can be put in place before the occurrence of a first IC, or after a first IC, especially when minor as a TIA. However, the diagnosis of TIA remains particularly difficult and it is necessary now to identify new tools for the diagnosis of transient ischemic attack. Our study focused on the identification of one or more molecules (called biological markers or biomarkers) present in the bloodstream of patients, which will serve to facilitate the differential diagnosis of patients with TIA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: September 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• TIA lasting 18h
• NIHSS < 0
• MRI diffusion hypersignal less than 5 ml
• follow up during 3 month
• written informed consent prior to any study procedures

Exclusion Criteria:

• Pregnant or breastfeeding women
• major comorbidity (cancer, chronic infection)
• recent trauma (less than 30 days) (cranial or extracranial)
• Surgical or endovascular recent surgery(within 30 days).
• Any old brain injury
• Any acute pathology likely to induce inflammation, hemostasis disorders ...
• Contraindications to MRI: Patients with a pacemaker, an implanted material activated by an electrical, magnetic or mechanical carriers hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants, claustrophobic ...
• Patient under guardianship

Related Conditions & MeSH terms

• Cerebrovascular Disorders
• Ischemia
• Ischemic Attack, Transient

Intervention

Biological:
• protein expression
Differential protein expression between the period of acute cerebral ischemia and the control period

Locations

Country	Name	City	State
France	Caen University Hospital	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in proteomic analysis from MPs or from plasma.	Identify one or more markers of transient ischemic attack by a proteomic analysis from MPs or from plasma.	baseline and 72h after TAI and 90 days after TAI